<div id="readability-page-1">BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C. Wainwright raised the firm’s price target on BioMarin to $60 from $55 with a Neutral rating on the shares. This sentiment was announced amid the acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), which the firm described as […]</div>

拜瑪林制藥

<p>H.C. Wainwright 將 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN）的目標股價從 55 美元上調至 60 美元，維持中性評級。這一調整是基於 BioMarin 收購 Amicus Therapeutics Inc.（NASDAQ:FOLD）的背景，預計該收購將穩定現金流，同時 Voxzogo 被預期為短期增長驅動因素。BioMarin 被認為是 2026 年值得購買的頂級 NASDAQ 股票之一</p>

HC Wainwright 表示，BioMarin 的收購 Amicus 穩定了現金流，而 Voxzogo 仍然是近期的主要驅動因素